Jorge Gavilondo - Concepedia

Author

Jorge Gavilondo

Centro de Ingeniería Genética y Biotecnología

Also Known As

Gavilondo, Jorge, J Gavilondo, J V Gavilondo, J. Gavilondo, J. V. GAVILONDO, J.V. Gavilondo, JORGE GAVILONDO, JORGE V. GAVILONDO, Jorge Gavilondo, Jorge V Gavilondo

110

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Centro de Ingeniería Genética y Biotecnología Center of Molecular Immunology (Cuba)Instituto de Oncología y Radiobiología Cuban Neuroscience Center Instituto de Gastroenterología

About

Jorge Gavilondo is an author at Centro de Ingeniería Genética y Biotecnología specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	846
2	Natural Sciences	4	4	116
3	Engineering	3	3	128
4	Health Sciences	1	1	48
5	Allergy	1	1	34

Jorge Gavilondo

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Development and validation of a quantitative ELISA for the measurement of PSA concentration Boris Acevedo, Yasser Perera, M Antonio Don ̃u Ruiz, Clinica Chimica Acta Biomarker (Medicine)Analytical InstrumentationMedicineDiagnostic TestBioanalysis	2002	101
An innovative sandwich ELISA system based on an antibody cocktail for gluten analysis Luis Sorell, Juan Antonio López, Israel Valdés, FEBS Letters	1998	86
Expression and characterization of an anti‐(hepatitis B surface antigen) glycosylated mouse antibody in transgenic tobacco (<i>Nicotiana tabacum</i>) plants and its use in the immunopurification of its target antigen Nadia Ramírez, M. Arias Rodríguez, Marta Ayala, Biotechnology and Applied Biochemistry Plant PhysiologyEngineeringMolecular PharmingImmunologyImmunodominance	2003	58
Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor M. Arias Rodríguez, Nadia Ramírez, Marta Ayala, Biotechnology and Bioengineering EngineeringBotanyImmunologyForeign MoleculeImmunotherapy	2004	50
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial Jorge Gavilondo, Francisco Hernández‐Bernal, Marta Ayala‐Ávila, Vaccine Vegf VaccineSpecific Active ImmunotherapyTumor ImmunologyCancer TherapeuticsVaccine Research	2014	48
Intra- and extracellular expression of an scFv antibody fragment in E. coli: effect of bacterial strains and pathway engineering using GroES/L chaperonins. Marta Dueñas, J Vázquez, Marta Ayala, PubMed Antibody FragmentE. ColiHumoral ResponseBacteriologyImmunology	1994	44
Ultrastructural evidences of HCV infection in hepatocytes of chronically HCV-infected patients Viviana Falcón, Nelson Acosta‐Rivero, Glay Chinea, Biochemical and Biophysical Research Communications Hcv InfectionHepatologyViral PersistenceViral HepatitisLiver Physiology	2003	39
Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants Yanelys Morera Díaz, Mónica Béquet‐Romero, Marta Ayala, Angiogenesis Cancer ImmunosurveillanceActive ImmunotherapyMedicineAnti-tumoral EffectImmunology	2008	37
Production of active anti-CD6 mouse/human chimeric antibodies in the milk of transgenic mice José Limonta, A. Pedraza, Armando Rodríguez, Immunotechnology HistocompatibilityAutoimmune DiseaseAllergyTransgenic Mouse ModelsImmunology	1995	34
CIGB-247: A VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors Mónica Béquet‐Romero, Yanelys Morera Díaz, Marta Ayala‐Ávila, Vaccine Tumor BiologyImmunologySpontaneous Lung MetastasisVegf-based Therapeutic VaccineBronchial Neoplasm	2012	33

Page 1